The effect of vitamin therapy on the course of chronic obstructive pulmonary disease in combination with iron-deficient conditions and with/without residual changes after cured pulmonary tuberculosis

March 28, 2019
976
Resume

Chronic obstructive pulmonary disease (COPD) is a widespread disease. In the conditions of the epidemic of pulmonary tuberculosis (PT), the number of people with residual changes after cured PT (RCPTs) is increases. All chronic diseases often lead to the development of iron deficiency states (IDS). However, we did not meet in literature the researches that studied the features of COPD/IDS in RCPTs patients and the effect on vitamin therapy (VT). We examined 71 patients with COPD and IDS, of which 38 were diagnosed with RCPTs. All patients before and after treatment were evaluated for clinical status, clinical examination, a study of respiratory function and determination of levels of anxiety and depression. It was found that among patients with COPD and COPD/RCPTs and existing IDS, which was included in the treatment regimen of VT compared with patients without using VT, there was more pronounced improvement according to clinical tests, increase of biochemical parame­ters (serum iron and percentage of saturation of transferrin by iron) and dynamic improvement in the psychological state, while forced expiratory volume-one second was likely to increase in patients who did not take VT. Also, the effect of pack-years of smoking on the course of the underlying disease when using VT is established.

Published: 28.03.2019

References:

  • de la Mora I.L., Martínez-Oceguera D., Laniado-Laborín R. (2015) Chronic airway obstruction after successful treatment of tuberculosis and its impact on quality of life. Int. J. Tuberc. Lung Dis., 19(7): 808–810.
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2017) GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD (https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/).
  • Kaplan A., Thomas M. (2017) Screening for COPD: the gap between logic and evidence. Eur. Respir. Rev., 26(143): 160113.
  • Kotsiou O.S., Zouridis S., Kosmopoulos M., Gourgoulianis K.I. (2018) Impact of the financial crisis on COPD burden: Greece as a case study. Eur. Respir. Rev., 27(147): 170106.
  • Meghji J., Simpson H., Squire S.B., Mortimer K. (2016) A Systematic Review of the Prevalence and Pattern of Imaging Defined Post-TB Lung Disease. PLoS One, 11(8): e0161176.
  • Plit M.L., Anderson R., Van Rensburg C.E. et al. (1998) Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis. Eur. Respir. J., 12(2): 351–356.
  • Sarkar M., Srinivasa., Madabhavi I., Kumar K. (2017) Tuberculosis associated chronic obstructive pulmonary disease. Clin. Respir. J., 11(3): 285–295.
  • van Buul A.R., Kasteleyn M.J., Chavannes N.H., Taube C. (2017) Association between morning symptoms and physical activity in COPD: a systematic review. Eur. Respir. Rev., 26(143): 160033.
  • van Kampen S.C., Wanner A., Edwards M. et al. (2018) International research and guidelines on post-tuberculosis chronic lung disorders: a systematic scoping review. BMJ Glob. Health, 3(4): e000745.
  • van Zyl Smit R.N., Pai M., Yew W.W. et al. (2010) Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. Eur. Respir. J., 35(1): 27–33.
  • Weiss G. (2002) Pathogenesis and treatment of anaemia of chronic disease. Blood Rev., 16(2): 87–96.
  • WHO (2007) Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach (https://www.who.int/gard/publications/GARD%20Book%202007.pdf).
  • WHO (2016) Global Tuberculosis Report 2016 (http://apps.who.int/medicinedocs/en/d/Js23098en/).
  • WHO (2018) Global tuberculosis report 2018 (https://www.who.int/tb/publications/global_report/en/).